AstraZeneca PLC's revisions to its MYSTIC trial evaluating its anti-PD-L1 durvalumab and anti-CTLA-4 tremelimumab in first-line non-small cell lung cancer (NSCLC) should expand the scope of what is possible with the trial, but it now runs the risk of being underpowered.
The new plan places slightly more emphasis on durvalumab as a monotherapy, despite AstraZeneca stating: "the focus remains on exploring...